Highlights Jun 29 - Jul 5, 2026
new every Sunday
This week brought new evidence on lasting personality shifts, reward circuitry, and the metabolism of a little-studied psychedelic. It also surfaced practical resources and ethical questions for clinical research, from ibogaine safety to false memories.
-
01
Classic psychedelics are linked to lasting increases in openness and reductions in neuroticism, with effects shaped by mystical experiences and ego dissolution
A longitudinal meta-analysis finds small, lasting increases in openness and decreases in neuroticism after classic psychedelic use.
-
02
A single dose of psilocybin reduces reward-seeking behavior by altering inhibitory brain cells in the prefrontal cortex, with effects linked to SST interneurons
Mouse research ties reduced reward seeking after one psilocybin dose to lasting changes in prefrontal SST interneurons.
-
03
Studie erfasst erstmals umfassend den Stoffwechsel von 25E-NBOH und identifiziert 51 Metaboliten als Grundlage für Konsumforschung und Forensik
Researchers identified 51 metabolites of 25E-NBOH, improving forensic detection and toxicological study of the potent psychedelic.
-
04
MAPS publishes a free open-access ibogaine Investigator's Brochure to support researchers with pharmacology, safety, dosing, and clinical development guidance
MAPS released a free ibogaine research guide covering pharmacology, dosing, cardiac safety, and clinical development.
-
05
Psychedelics and false memories raise clinical and ethical concerns when suggestibility, trauma work, and psychedelic-assisted therapy intersect in vulnerable states
The analysis warns that suggestibility and memory malleability can produce false trauma narratives, demanding stronger therapy safeguards.
-
06
A psilocybin study found that the same psychedelic experience can increase harmony or intensify social division depending on a participant's preexisting ideological lens
A study challenges claims of universal prosocial effects by showing that prior ideology can shape psilocybin's social outcomes.
-
07
Discovering Ketamine with Dr. Edward Domino
Edward Domino recounts ketamine's first human tests, psychiatric significance, and ethically fraught origins in prison research.